Satellite Symposia at the 2024 Oncology Nursing Society Congress
April 24-27, 2024
April 24-27, 2024
Artificial intelligence use in prostate cancer encompasses 4 main areas including diagnostic imaging, prediction of outcomes, histopathology, and treatment planning.
The introductions of immunotherapy and first-line combinations have led to major changes in systemic anti-cancer treatment (SACT) options and outcomes in metastatic renal cell carcinoma…
Thursday, May 23, 2024 12:00PM – 1:00PM ET Online Webinar will also be streamed virtually Register Today Watch the Friends x PICI May 6th Cell…
In recent years, Clinical Trials Day has become a chance to raise public awareness of the impact of research studies and to recognize the importance…
The FDA has withdrawn the approval of infigratinib for previously treated, FGFR2-positive, advanced cholangiocarcinoma.
Sarah Wilder wanted a way to give back while her husband received treatment at MD Anderson for stage IV prostate cancer. A blood drive provided…
Jubilee Brown, MD, highlights the RAS/MAPK pathway in low-grade serous ovarian cancer and research with avutometinib/defactinib that prompted RAMP 301.
Homologous recombination deficiency tests are used routinely in the clinic to determine which patients get PARP inhibitors. To access this subscriber-only content please log in…
This retrospective analysis of the PRODIGE-35 trial showed that LV5FU2 maintenance after 8 cycles of FOLFIRINOX is feasible in patients treated first line
Samilia Obeng-Gyasi, MD, MPH, expands on the impact of social determinants of health on breast cancer care.